View Archive »
About The Cover
Visualizing Two-Compartment Tumor Metabolism, with Metabolic Marker Proteins: MCT4 and TOMM20. Human breast cancer samples (from primary tumors or lymph node metastases) were immuno-stained with antibodies directed against MCT4 (shown in RED) and TOMM20 (shown in BROWN). Image was digitaly enhanced for the cover of Oncotarget. See Sotgia et al.
|
|
Table of Contents
Editorial
|
| Adoptive Tcell therapy to treat liver cancer: Is the liver microenvironment key |
|
https://doi.org/10.18632/oncotarget.1179
|
| 1117-1118 |
|
| Cancer detection using wholegenome sequencing of cell free DNA |
|
https://doi.org/10.18632/oncotarget.1183
|
| 1119-1120 |
|
| Regulation of Mdm2 mRNA Stability by RNAbinding Protein RNPC1 |
|
https://doi.org/10.18632/oncotarget.1185
|
| 1121-1122 |
|
| Restoring hemidesmosomes to prevent cancer cell invasiveness |
|
https://doi.org/10.18632/oncotarget.1196
|
| 1123-1124 |
|
| ATM is activated in blood monocytes after tumor radiation |
|
https://doi.org/10.18632/oncotarget.1286
|
| 1125 |
Editorial Broadcast
|
| A new Achilles Heel in breast cancer |
|
https://doi.org/10.18632/oncotarget.1178
|
| 1126-1127 |
|
| Overcoming treatment resistance in acute promyelocytic leukemia and beyond |
|
https://doi.org/10.18632/oncotarget.1244
|
| 1128-1129 |
Reviews
|
| Understanding the role of NRF2regulated miRNAs in human malignancies |
|
https://doi.org/10.18632/oncotarget.1181
|
| 1130-1142 |
Research Papers
|
| Radiation therapy induces the DNA damage response in peripheral blood |
|
https://doi.org/10.18632/oncotarget.1084
|
| 1143-1148 |
|
| Gli1 Transcriptional Activity is Negatively Regulated by AKT2 in Neuroblastoma |
|
https://doi.org/10.18632/oncotarget.1074
|
| 1149-1157 |
|
| Targeting mixed lineage kinases in ERpositive breast cancer cells leads to G2/M cell cycle arrest and apoptosis |
|
https://doi.org/10.18632/oncotarget.1093
|
| 1158-1171 |
|
| Identification of pregnancyassociated plasma protein A as a migrationpromoting gene in malignant pleural mesothelioma cells: a potential therapeutic target |
|
https://doi.org/10.18632/oncotarget.1126
|
| 1172-1184 |
|
| Combining TRAIL with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling |
|
https://doi.org/10.18632/oncotarget.1162
|
| 1185-1198 |
|
| Annexin A2 is regulated by ovarian cancerperitoneal cell interactions and promotes metastasis |
|
https://doi.org/10.18632/oncotarget.1122
|
| 1199-1211 |
|
| Small MoleculeInduced Mitochondrial Disruption Directs Prostate Cancer Inhibition via Unfolded Protein Response Signaling |
|
https://doi.org/10.18632/oncotarget.1130
|
| 1212-1229 |
|
| Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival |
|
https://doi.org/10.18632/oncotarget.1145
|
| 1230-1240 |
|
| A novel Mcl1 variant inhibits apoptosis via increased Bim sequestration |
|
https://doi.org/10.18632/oncotarget.1147
|
| 1241-1252 |
|
| Combination therapy with antiErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Nonsmall Cell Lung Cancer |
|
https://doi.org/10.18632/oncotarget.1141
|
| 1253-1265 |
|
| PTEN loss represses glioblastoma tumor initiating cell differentiation via inactivation of Lgl1 |
|
https://doi.org/10.18632/oncotarget.1164
|
| 1266-1279 |
|
| Critical role of zinc finger protein 521 in the control of growth clonogenicity and tumorigenic potential of medulloblastoma cells |
|
https://doi.org/10.18632/oncotarget.1176
|
| 1280-1292 |
|
| HMGA1 promotes metastatic processes in basallike breast cancer regulating EMT and stemness |
|
https://doi.org/10.18632/oncotarget.1136
|
| 1293-1308 |
Research Perspectives
|
| Cancer Metabolism: New Validated Targets for Drug Discovery |
|
https://doi.org/10.18632/oncotarget.1182
|
| 1309-1316 |
|
| A Tumor initiating cellenriched prognostic signature for HER2+:ERα breast cancer; rationale new features controversies and future directions |
|
https://doi.org/10.18632/oncotarget.1170
|
| 1317-1328 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
